Enlivex (ENLV) has released an update.
Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Enlivex Therapeutics has announced the successful dosing of the first patient in a Phase I trial to test Allocetra, a potential new treatment for psoriatic arthritis. The study aims to recruit six patients unresponsive to conventional therapies, exploring Allocetra’s safety and therapeutic effects. This development could position Enlivex at the forefront of addressing significant unmet needs in a growing psoriatic arthritis market.
For further insights into ENLV stock, check out TipRanks’ Stock Analysis page.
